Stockreport

Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China

GENEREX BIOTECHNOLOGY  (GNBT) 
US:NASDAQ Investor Relations: generex.com/investor
PDF Generex to receive a $700,000 USD up-front license fee; deal includes milestone payments and royalties MIRAMAR, Fla.--(BUSINESS WIRE)-- Genere [Read more]